Research indicates that inhibiting FABP4 activity can effectively reduce body weight and enhance insulin sensitivity in obesity models, thereby reinforcing the potential of FABP4 as a target for intervention in metabolic diseases (Chung et al., 2021). The gene discussed is FABP4; the disease is metabolic disease.